Trial Profile
A 4 Day, Randomized Study to Evaluate the Potential of CCP-020 (Diacerein 1%) Topical Ointment to Induce a Phototoxicity Skin Reaction in Healthy Subjects, Using a Controlled Photopatch Test
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Feb 2020
Price :
$35
*
At a glance
- Drugs Diacerein (Primary)
- Indications Bullous pemphigoid; Epidermolysis bullosa; Gout; Joint disorders; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Castle Creek Pharmaceuticals
- 26 Mar 2018 New trial record